Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.69 |
| ▸ | MAOB | P27338 | 2/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | BCL2 | P10415 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 5/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18015843 | 0.86 | TAAR1 (0.55) | TAAR1MAOBALOX5ESR2BCL2 | |
| SCHEMBL11326904 | 0.85 | BCL2 (0.53) | TAAR1MAOBBCL2 | |
| SCHEMBL19523120 | 0.85 | MAOB (0.69) | TAAR1MAOBALOX5ESR2GRM2 | |
| SCHEMBL31491189 | 0.82 | TAAR1 (0.71) | TAAR1MAOBALOX5ESR2PGR | |
| SCHEMBL16394285 | 0.82 | TAAR1 (0.71) | TAAR1MAOBALOX5ESR2PGR | |
| SCHEMBL28636691 | 0.82 | MAOB (0.65) | TAAR1MAOBALOX5ESR2GRM2 | |
| SCHEMBL2690730 | 0.82 | TAAR1 (1.00) | TAAR1MAOBALOX5ESR2 | |
| SCHEMBL9007144 | 0.81 | BCL2 (0.65) | TAAR1BCL2 | |
| SCHEMBL29924029 | 0.81 | BCL2 (0.65) | TAAR1BCL2 | |
| SCHEMBL14071527 | 0.81 | CHKA (0.58) | TAAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452464-B1 | PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-11174219-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2017191098-A1 | PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-09 | — | — | WO | disclosed |
| US-9802904-B2 | Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-10-31 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| EP-2320886-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORP (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-3153501-A1 | GLUCAGON ANTAGONISTS | Metabasis Therapeutics, Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2773335-B1 | OXALIC ACID AMIDES AS NEPRILYSIN INHIBITORS, PHARMACEUTICAL COMPOSITION THEREOF AND PREPARATION THEREOF | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150344443-A1 | INHIBITORS OF THE USP1/UAF1 DEUBIQUITINASE COMPLEX AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN (US) | 2015-12-03 | — | — | US | disclosed |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2008116156-A2 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS ASSOCIATED WITH MITOCHONDRIAL FUNCTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053193-A2 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053725-A2 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070105844-A1 | Therapeutic compositions and methods | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105844-A1 | Therapeutic compositions and methods | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | US | disclosed |
| WO-2007050587-A2 | THERAPEUTIC COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174219-B2 | Neprilysin inhibitors | MME, REN, ACE | TAAR1 595/4885MAOB 282/4885ALOX5 4201/4885 |
| US-20070105844-A1 | Therapeutic compositions and methods | GABRB3, GABRR3, GABRB2 | TAAR1 661/4885MAOB 215/4885ALOX5 514/4885 |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | TAAR1 1998/4885MAOB 2853/4885ALOX5 3995/4885 |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | ATP5F1A, ATP5MF, MT-ATP6 | TAAR1 4797/4885MAOB 2528/4885ALOX5 670/4885 |
| US-20150344443-A1 | INHIBITORS OF THE USP1/UAF1 DEUBIQUITINASE COMPLEX AND USES THEREOF | USP1, UHRF1, UBQLN1 | TAAR1 3659/4885MAOB 2843/4885ALOX5 4067/4885 |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | BAD, GABRA5, GABRB1 | TAAR1 419/4885MAOB 2222/4885ALOX5 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.